A cystic jaw lesion with an unexpected mural component
A 34-year-old woman presents with a 2.4 cm well-corticated radiolucency at the right mandibular angle, intimately associated with the crown of an impacted third molar. Enucleation is performed. Microscopy shows a thin, non-keratinized stratified squamous lining with focal mucous cells and a few ciliated cells; the fibrous wall contains a small (1.5 mm) nodule of ameloblastomatous epithelium with peripheral palisading and reverse polarity. The surgical margin is uninvolved. The patient is healthy, takes no medications, and has no family history of jaw tumors. A colleague argues the diagnosis is 'dentigerous cyst with reactive change' and recommends no further treatment; another suggests segmental resection.
1. What is the most defensible diagnosis, and how do you justify it against the two competing interpretations?
Read the worked answer
The findings combine a cyst with a dentigerous relationship and a mural epithelial nodule showing ameloblastic features, so the diagnosis is dentigerous cyst with a mural ameloblastoma (unicystic ameloblastoma, mural subtype).
Reasoning against alternatives:
- Pure dentigerous cyst: the lining's mucous and ciliated metaplasia is common and benign, but it does not explain an ameloblastomatous mural nodule with palisading and reverse polarity.
- Ameloblastoma arising de novo: the intact crown association and thin cyst lining favor origin in a dentigerous cyst.
- Segmental resection: the nodule is 1.5 mm and margins are clear; mural ameloblastomas confined to the wall behave far less aggressively than solid multicystic tumors.
The key judgment is that mural ameloblastic change is not 'reactive' - it is a neoplastic component that changes surveillance and recurrence risk, even when small.
2. Outline a management and follow-up plan, and state the single most important histologic variable that would change it.
Read the worked answer
Plan: conservative but complete removal of the cyst and nodule with curettage of the socket, plus clinical and radiographic follow-up (e.g., at 6 months, then annually for at least 5 years), given recurrence risk in mural unicystic ameloblastoma.
Variable that changes the plan: evidence of intraluminal/intramural extension beyond the fibrous wall or involvement of the mucosal/surgical margin, or a much larger nodule with solid growth pattern - that would push toward wider resection. Nodule size and margin status, not the presence of mucous metaplasia, drive the decision.
Note that the mural component, not the dentigerous cyst, determines prognosis, so follow-up should be framed around recurrence risk.